Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer.

Abstract

Nab-Paclitaxel plus Gemcitabine and FOLFOXThis randomized, open-label, phase II trial compared nab-paclitaxel/gemcitabine followed by modified FOLFOX versus nab-paclitaxel/gemcitabine alone for the first-line treatment of metastatic pancreatic ductal adenocarcinoma. Patients receiving nab-paclitaxel plus gemcitabine followed by modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) had a 12-month and 24-month overall survival of 55.3% and 22.4%, respectively, compared with 35.4% and 7.6% in the control group; there was a higher incidence of grade 3 or higher neutropenia and thrombocytopenia. No significant differences in febrile neutropenia, epistaxis or hemorrhage of grade 3 or higher in either group were reported. Two toxic deaths (2.6%) occurred in the experimental group.

• Authors: Alfredo Carrato, Roberto Pazo-Cid, Teresa Macarulla, Javier Gallego, Paula Jiménez-Fonseca, Fernando Rivera, Maria Teresa Cano, Mercedes Rodriguez-Garrote, Carles Pericay, Inmaculada Alés, Laura Layos, Begoña Graña, Vega Iranzo, Inmaculada Gallego, Rocio Garcia-Carbonero, Inmaculada Ruiz de Mena, Carmen Guillén-Ponce, Enrique Aranda
• Journal: NEJM evidence (NEJM Evid) Vol. 3 Issue 2 Pg. EVIDoa2300144 (Feb 2024) ISSN: 2766-5526 [Electronic] United States
• PMID: 38320486 (Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)

Chemical References

• 130-nm albumin-bound paclitaxel
• Albumins
• Deoxycytidine
• Gemcitabine
• Paclitaxel

Topics

• Humans
• Albumins
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Deoxycytidine (adverse effects)
• Gemcitabine
• Paclitaxel (adverse effects)
• Pancreatic Neoplasms (drug therapy)